source
- Sofinnova closes second crossover fund at €725M for late-stage European biotechsSofinnova Partners has secured €725 million ($815 million) for its second crossover fund, which it said would fill the financing gap for late-stage European biopharma and medtech companies. Europe…Endpoints · 1h ago↗ source
- One of Europe’s leading VCs banks a €725M ‘crossover’ fundSofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.BioPharma Dive · 1h ago↗ source
- Tandem Mobi sees FDA clearance for tubeless AID systemTandem Diabetes Care has picked up FDA clearance of its Tandem Mobi system, a tubeless automated insulin delivery device cleared for up to seven days of wear.